Home
Faculty Directory
Vern L. Schramm, Ph.D.

Vern L. Schramm, Ph.D.

Ruth Merns Chair in Biochemistry

Area of Research: Enzymatic transition states are solved by isotope effects and quantum chemistry. This knowledge permits drug design for cancers, antibiotics and other disorders. Protein dynamics in catalysis is a second focus.

Contact Information

718.430.2813718.430.8565vern.schramm@einsteinmed.edu

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Golding Building, Room 301
Bronx, NY 10461

Research Profiles Einstein Media Expert PubMed Portal

Is this your profile? Edit profile

Professional Interests

Overview

Enzymes catalyze virtually all of the chemical transformations necessary for biological life. Knowledge of the transition-state structure of enzymatic reactions permits the design of powerful inhibitors. Methods have been developed in this laboratory for the experimental determination of the geometric and charge features which characterize enzymatic transition states. This information is then used for the logical design of transition-state inhibitors which have the potential to be new biologically active agents. Specific projects include:

Human genetic deficiency of purine nucleoside phosphorylase causes a specific T-cell insufficiency. Our inhibitors of this enzyme are powerful anti T-cell agents. Two inhibitors are now in human clinical trials against human T-cell cancers and gout. Three T-cell cancer indications for these drugs have received orphan drug status from the FDA and several phase II trials are in progress. Phase II clinical trials have been completed for gout using our second-generation inhibitor. Third-generation and fourth-generation inhibitors are now being characterized.

Purine salvage is essential for growth of parasitic protozoa. A family of powerful inhibitors has been prepared against these enzymes from the malaria parasite. Promising results have been obtained in cell culture studies. One of these inhibitors stops the growth of malaria parasites in primate malaria. Preclinical research is underway, intended to lead to human trials in the next few years.

Experimental cancer chemotherapy uses plant toxins coupled to a recognition element for cancer cells. The transition state structure of saporin is being determined to guide the design of inhibitors. These will limit the side-effects of the toxin molecules remaining in the circulation or released from lysed cancer cells. Inhibitors are being synthesized and tested for efficiency, and constructs with saporin are being investigated as anticancer agents.

Research projects also involve S-adenosylmethionine recycling and methyl transfer reactions. Methyltransfer reactions are central to the epigenetic control pathways regulating growth, development, gene expression and cancer. New targets for transition state analysis and drug design are DNA methyltransferases, protein methyltransferases and metabolic enzymes forming and using S-adenosylmethionine. Related to these pathways are MTAP, a cancer target and MTAN, a target for bacterial antibiotics.

Students in this laboratory can receive training in enzymology, catalysis, protein expression, inhibitor design, computer modeling, inhibitor synthesis, and in drug metabolism studies in cells and animals. Active collaborations occur with laboratories specializing in NMR, X-ray crystallography, mass spectroscopy, synthetic organic chemistry, cancer and medicine. Projects can be designed to include several of these research approaches through active collaborative research programs.

Selected Publications

Harijan, R.K., Zoi, I., Antoniou, D., Schwartz, S.D., Schramm, V.L. “Inverse enzyme isotope effects in human purine nucleoside phosphorylase with heavy asparagine labels”. Proc Natl Acad Sci U S A. 115, E6209-E6216 (2018). PMC29915028

Schramm, V.L., Schwartz, S.D. “Promoting Vibrations and the Function of Enzymes. Emerging Theoretical and Experimental Convergence.” Biochemistry 57, 3299-3308 (2018). PMC6008225

Ducati, R.G., Namanja-Magliano, H.A., Harijan, R.K., Fajardo, J.E., Fiser, A., Daily, J.P., Schramm, V.L. “Genetic resistance to purine nucleoside phosphorylase inhibition in Plasmodium falciparum”. Proc Natl Acad Sci U S A. 115, 2114-2119 (2018). PMC5834662

Harris, L.D., Harijan, R.K., Ducati, R.G., Evans, G.B., Hirsch, B.M., Schramm, V.L. “Synthesis of bis-Phosphate Iminoaltritol Enantiomers and Structural Characterization with Adenine Phosphoribosyltransferase.” ACS Chem Biol. 13, 152-160 (2018). PMID29178779

Evans, G.B., Tyler, P.C., Schramm, V.L. “Immucillins in Infectious Diseases.” ACS Infect Dis. 4, 107-117 (2018). PMC6034505

Ducati RG, Firestone RS, Schramm VL. “Kinetic Isotope Effects and Transition State Structure for Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase from Plasmodium falciparum.” Biochemistry 56, 6368-6376 (2017). PMC5926801

Stratton, C.F., Poulin, M.B., Schramm, V.L. “Binding Isotope Effects for Interrogating Enzyme-Substrate Interactions.” Methods Enzymol 596, 1-21 (2017). PMID28911767

Firestone, R.S., Schramm, V.L. “The Transition-State Structure for Human MAT2A from Isotope Effects.” J. Am. Chem. Soc. 139, 13754-13760 (2017). PMC5674783

Moggré, G.J., Poulin, M.B., Tyler, P.C., Schramm, V.L., Parker, E.J. “Transition State Analysis of Adenosine Triphosphate Phosphoribosyltransferase.” ACS Chem Biol. 12, 2662-2670 (2017). PMID28872824

Namanja-Magliano HA, Evans GB, Harijan RK, Tyler PC, Schramm VL. “Transition State Analogue Inhibitors of 5'-Deoxyadenosine/5'-Methylthioadenosine Nucleosidase from Mycobacterium tuberculosis.” Biochemistry 56, 5090-5098 (2017). PMC6019266

Gebre, S.T., Cameron, S.A., Li, L., Babu, Y.S., Schramm, V.L. “Intracellular rebinding of transition-state analogues provides extended in vivo inhibition lifetimes on human purine nucleoside phosphorylase. J. Biol. Chem. 292, 15907-15915 (2017). PMC5612120

Harijan, R.K., Zoi, I., Antoniou, D., Schwartz, S.D. and Schramm, V.L. “Catalytic-site design for inverse heavy-enzyme isotope effects in human purine nucleoside phosphorylase.” Proc. Natl. Acad. Sci. 114, 6456-6461 (2017). PMC5488955

Firestone, R.S., Cameron, S.A., Karp, J.M., Arcus, V.L. and Schramm, V.L. “Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5’-Methylthioadenosine.” ACS Chem Biol 12, 464-473 (2017). PMC5462123

Stratton, C.F., Poulin, M.B., Du, Q. and Schramm, V.L. “Kinetic Isotope Effects and Transition state Strucutre for Human Phenylethanolamine N-Methyltransferase.” ACS Chem Biol 12, 342-346 (2017) PMC5553282

In the News

More Media Coverage

Tuesday, May 1, 2012

TheScientist features a cover article by Vern Schramm, Ph.D., on transition-state analogs, compounds he synthesizes that bind to enzymes and short-circuit specific chemical reactions, and their potential for a powerful new line of drugs. Dr. Schramm is a leader in the field and the article highlights some of his discoveries, including potential treatments for cancer, malaria, gout and an antibiotic that defies resistance. Dr. Schramm is professor and chair of biochemistry and the Ruth Merns Chair in Biochemistry at Einstein.
Tuesday, March 13, 2012

New Scientist interviews Vern Schramm, Ph.D., about his research on transition state analogs, a class of drugs he has been developing that target and neutralize specific enzymes in order to combat disease. Dr. Schramm is professor and Ruth Merns Chair in Biochemistry at Einstein.

Quick Links

Faculty Profile

Vern L. Schramm, Ph.D.

Contact Information

Professional Interests

Selected Publications

Related News

Research Brief

Taming a Notorious Bacterium

Research Brief

New Approach Against a Killer Bacterium

In the News

About Einstein

Administration

Alumni

Careers

Centers (Research)

Contact Us

Departments

Diversity

Donors

Education

Einstein Senate

Faculty Directory

Health

INTRANET

Library

Luminis Portal

Newsroom

Policies

Research

Video

Visitors

Webmail